Pain
Conditions
Keywords
Pharmacokinetics
Brief summary
This study is designed to assess bioequivalence between one test and one reference formulation used for temporary relief of pain. The results will help decide if the new medicine is likely to provide pain relief similar to the product being sold.
Detailed description
The study is a single dose, randomized, two-way crossover study in 32 healthy male and female volunteers, minimum of 14 of each gender. Two doses of study medication will be given as single doses on two separate treatment visits. A washout of at least 48 hours will separate the treatment visits. Each visit will include an overnight fast at the clinic and 19 blood samples drawn for pharmacokinetic analyses. Tolerability of the treatments will be evaluated in terms of reported and observed adverse events (AE).
Interventions
DRUGIbuprofen
A single 5 mL dose of 200 mg ibuprofen/5 mL experimental suspension, administered orally, with a 48-hour washout between visits
Sponsors
McNeil AB
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy (per protocol-specified parameters) male or female subjects (14 of each gender) between the ages of 18 and 50 years, inclusive. * Non- or ex-tobacco user, being defined as someone who completely stopped smoking or using any form of tobacco for at least 12 months before screening visit of this study. * For females: if not postmenopausal, agrees to use a protocol-specified means of contraception or declared absence of sexual contact with a male partner during the study. * For males: No pregnant spouse or partner at screening and willingness to protect potential spouse or partner from becoming pregnant during the study. * Body Mass Index (BMI) within protocol-specified parameters. * A personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study. * Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures specified in the protocol.
Exclusion criteria
* Evidence or history of an acute or chronic medical or psychiatric condition, laboratory abnormality, or drug use that, in the judgment of the investigator or an authorized physician, may compromise subject safety or the interpretation of results. * Females: Pregnant or breast-feeding * Treatment with an investigational drug within 3 months preceding the first dose of study treatment. * History of regular alcohol consumption outside the protocol-specified allowances. * Donation or loss of blood within 3 months prior to the first treatment visit if the estimated lost blood volume equaled or exceeded 450 mL. * Relationship to persons involved directly with the conduct of the study, or their families.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cmax | During 12 hours post-dose | Maximum observed plasma concentration (Cmax), is the maximum (peak) concentration (amount of drug) measured in blood plasma after a dose administration. |
| AUCt | During 12 hours post-dose | Area under the plasma concentration-vs.-time curve from start of drug administration until last measured concentration (AUCt), is a measure of how much of the drug reaches the bloodstream during the sampling period. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Terminal Elimination Rate Constant (λz) | During 12 hours post-dose | The terminal elimination rate constant (λz) describes the rate at which a drug is eliminated from the body. |
| AUC∞ | During 12 hours post-dose | Area under the plasma concentration-vs.-time curve from start of drug administration and extrapolated to infinity (AUC∞), is a measure of how much of the drug ever reaches the bloodstream. |
| Mean Residence Time (MRT) | During 12 hours post-dose | Mean residence time (MRT) is the mean time a drug molecule resides in the body. |
| t½ | During 12 hours post-dose | Terminal half-life (t½) is the time required for the plasma concentration (as well as the amount of drug in the body) to fall by one-half. |
| tmax | During 12 hours post-dose | The time at which maximum concentration is reached (tmax) |
Countries
Sweden
Outcome results
None listed